| prolactin induction of VEGF-C and Runx2 was inhibited partly by Carboxypeptidase-D inhibitors, implicating nitric oxide , produced by PRL-regulated Carboxypeptidase-D, in breast cancer progression | Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
Thomas LN, Chedrawe ER, Barnes PJ, Too CKL. | 03/17/2018 |
| Carboxypeptidase-D (CPD) overexpression coincides with high-grade lung cancer and the CPD overexpression could reverse the inhibitory effects of miR-214 | microRNA-214 Governs Lung Cancer Growth and Metastasis by Targeting Carboxypeptidase-D.
Zhao X, Lu C, Chu W, Zhang Y, Zhang B, Zeng Q, Wang R, Li Z, Lv B, Liu J. | 02/18/2017 |
| The human carboxypeptidase D transthyretin-like domain forms amyloid under physiological conditions. | Amyloid formation by human carboxypeptidase D transthyretin-like domain under physiological conditions.
Garcia-Pardo J, Graña-Montes R, Fernandez-Mendez M, Ruyra A, Roher N, Aviles FX, Lorenzo J, Ventura S., Free PMC Article | 03/7/2015 |
| Prolactin and R1881, acting through Stat5 and androgen receptor, act cooperatively to stimulate CPD gene transcription in breast cancer cells. | Prolactin/Stat5 and androgen R1881 coactivate carboxypeptidase-D gene in breast cancer cells.
Koirala S, Thomas LN, Too CK., Free PMC Article | 11/8/2014 |
| CPD immunostaining and testosterone/prolactin-stimulated CPD expression were higher in prostate cancer than benign tissues/cells. Elevated CPD increased NO production, which was abolished when both androgen and prolactin receptors were inhibited. | Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.
Thomas LN, Merrimen J, Bell DG, Rendon R, Goffin V, Too CK. | 06/14/2014 |
| Carboxypeptidase D (CPD) is frequently upregulated in hepatocellular carcinoma; targeting CPD inhibits hepatocellular carcinoma cell proliferation through induction of G1 cell-cycle arrest and apoptosis. | SiRNA-targeted carboxypeptidase D inhibits hepatocellular carcinoma growth.
Jin T, Fu J, Feng XJ, Wang SM, Huang X, Zhu MH, Zhang SH. | 02/8/2014 |
| Either high glucose or insulin (with low glucose) up-regulates beta-cell CPD (but not CPE). | Differential regulation and localization of carboxypeptidase D and carboxypeptidase E in human and mouse β-cells.
Chu KY, Briggs MJ, Albrecht T, Drain PF, Johnson JD. | 11/26/2011 |
| prolactin or E2 up-regulated CPD mRNA and protein expression in MCF-7 breast cancer cells promoting their survival | Prolactin and estrogen up-regulate carboxypeptidase-d to promote nitric oxide production and survival of mcf-7 breast cancer cells.
Abdelmagid SA, Too CK. | 01/21/2010 |
| First report to demonstrate carboxypeptidase D as part of the transforming growth factor (TGF)-beta pathway as a TGF-beta target gene implicated in the pathogenesis of lupus erythematosus. | Carboxypeptidase D: a novel TGF-beta target gene dysregulated in patients with lupus erythematosus.
Hoff NP, Degrandi D, Hengge U, Pfeffer K, Wurthner JU. | 01/21/2010 |
| Palmitoylation of carboxypeptidase D has a role in intracellular trafficking | Palmitoylation of carboxypeptidase D. Implications for intracellular trafficking.
Kalinina EV, Fricker LD. | 01/21/2010 |
| The isolation and characterization of CPD from several haematopoietic tumour cells are reported. | Characterization of a novel, cytokine-inducible carboxypeptidase D isoform in haematopoietic tumour cells.
O'Malley PG, Sangster SM, Abdelmagid SA, Bearne SL, Too CK., Free PMC Article | 01/21/2010 |
| CPD releases C-terminal Arg from peptides to provide the precursor substrate for inducible nitric oxide synthase, which enhances nitric oxide synthesis in macrophages. | Carboxypeptidase D is up-regulated in raw 264.7 macrophages and stimulates nitric oxide synthesis by cells in arginine-free medium.
Hadkar V, Skidgel RA. | 10/1/2004 |